Suppression of late asthmatic response by low-dose oral administration of interferon-beta in the guinea pig model of asthma.
We investigated the anti-asthmatic effects of low-dose oral and subcutaneous administration of interferon-beta (IFN-beta) on an ovalbumin (OVA)-sensitized and challenged guinea pig model of asthma. Subcutaneous administration of IFN-beta suppressed the eosinophil infiltration by 14.2% of the control and the respiratory resistance (Rrs) by 58.2% at 2.0 MIU/kg. Oral administration of IFN-beta inhibited the late asthmatic response (LAR) by suppressing the increase of Rrs by 29% of the control at 1 IU/ml and the eosinophil infiltration into the trachea and lung by 34.6% at the optimum dosage of 10 IU/ml. Both subcutaneous and oral administration could not inhibit the early asthmatic response (EAR). Additionally we found 2',5'-oligoadenylate synthetase (2',5'-OAS) induction by low-dose oral administration (LDOA) of IFN-beta to the same extent as by subcutaneous administration in whole blood in vivo. These data suggest that LDOA of IFN-beta would have some clinical benefit for patients with asthma.
Satoh
Y
Y
Department of Microbiology, Hokkaido University School of Medicine, Sapporo, Japan. satouy@med.hokudai.ac.jp
Kasama
K
K
Kuwabara
M
M
Yimin
Diao
H Y
HY
Nakajima
H
H
Kohanawa
M
M
Minagawa
T
T
D015088:2',5'-Oligoadenylate Synthetase / Q000096:biosynthesis; D000284:Administration, Oral; D000818:Animals; D001249:Asthma / Q000188:drug therapy*; D002452:Cell Count / Q000187:drug effects; D004790:Enzyme Induction; D004804:Eosinophils / Q000187:drug effects; D006168:Guinea Pigs; D006801:Humans; D007165:Immunosuppression Therapy; D007279:Injections, Subcutaneous; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male
D016899:Interferon-beta; D015088:2',5'-Oligoadenylate Synthetase